13778-37-5

Basic information

• Product Name: STISHOVITE
• Synonyms: STISHOVITE
• CAS NO: 13778-37-5
• Molecular Formula: O2Si
• Molecular Weight: 60.08
• Mol File: 13778-37-5.mol
• Article Data: 123

Chemical Properties

• Appearance: /
• CAS DataBase Reference: STISHOVITE(CAS DataBase Reference)
• NIST Chemistry Reference: STISHOVITE(13778-37-5)
• EPA Substance Registry System: STISHOVITE(13778-37-5)

Safety Data

• Hazardous Substances Data: 13778-37-5(Hazardous Substances Data)

Upstream product

• 78-10-4 tetraethoxy orthosilicate 
• 1187874-94-7 3-trifluoromethyl-4-hydroxybenzeneboronic acid 
• 1451393-40-0 (3-chloro-5-(trifluoromethoxy)phenyl)boronic acid 
• 172975-69-8 3,5-dimethylphenyl boronic acid 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 849062-37-9 (3-bromo-5-fluorophenyl)boronic acid 
• 75-85-4 tert-Amyl alcohol 
• 497832-98-1 4-bromo-1-methyl-5-(trifluoromethyl)-1H-pyrazole 
• 123-91-1 1,4-dioxane 
• 36901-75-4 (2-bromobenzyl)triphenylphosphonium bromide 
• 564483-18-7 XPhos 
• 73183-34-3 bis(pinacol)diborane 
• 445303-70-8 1-Bromo-3-(1,1-difluoro-ethyl)-benzene 

Downstream Products

• 134892-42-5 SKF 190851 
• 73671-86-0 (4aR,4bS,6aS,7S,9aS,9bS,11aR)-1,4a,6a-Trimethyl-2-oxo-hexadecahydro-indeno[5,4-f]quinoline-7-carboxylic acid diethylamide 
• 81864-29-1 N-(2,2-dimethylbenzo[1,3]dioxol-5-yl)acetamide 

Relevant articles and documents

CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.

COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.

TEMPERATURE-SENSITIVE NANO SILVER CONTROLLED-RELEASE SMART ANTIBACTERIAL COATING AND PREPARATION METHOD THEREFOR

This present invention discloses a temperature-sensitive nano-silver controlled release antibacterial coating composite, which is comprises: water, acrylic, polyurethane resin, temperature-sensitive nano-silver controlled release antibacterial agent, dispersant, curing agent, defoamer, filming additive and leveling agent. By adsorbing nano silver particles into the pores of mesoporous SiO2 modified by poly N-isopropyl acrylamide, we successfully prepared a temperature-sensitive nano-silver controlled release antibacterial agent. By adding the prepared agent to the conventional coating composite, we achieved “on-off” control of the antibacterial properties of coating composite. Through the control of temperature, the release of nano-silver in the mesoporous nano-silica of the coating film layer is controlled. This control method is not only to protect the nano-silver, but also to adjust the strength of the anti-bacterial properties according to the actual demands and improve the use-efficiency of nano silver particles. This invention is in line with the new concept of “Intelligent Age” in the 21st century.